Relation of reduced expression of MiR-150 in platelets to atrial fibrillation in patients with chronic systolic heart failure.
Atrial fibrillation (AF) is associated with poor prognosis in patients with heart failure (HF). Although platelets play an important role in rendering a prothrombotic state in AF, the exact mechanism by which the effect is mediated is still debated. MicroRNAs (miRNAs), which have been shown to be involved in a variety of cardiovascular conditions, are abundant in platelets and in a cell-free form in the circulation. In the present study, we performed a genome-wide screen for miRNA expression in platelets of patients with systolic HF and in controls without cardiac disease, in pursuit of specific miRNAs that are associated with the presence of AF. MiRNA expression was measured in platelets from 50 patients with systolic HF and 50 controls, of which, samples from 41 patients with HF and 35 controls were used in the final analysis because of a quality control process. MiR-150 expression was 3.2-fold lower (p = 0.0003) in platelets of patients with HF with AF relative to those without AF. A similar effect was seen in serum samples from the same patients, in which miR-150 levels were 1.5-fold lower (p = 0.004) in patients with HF with AF. Furthermore, the serum levels of miR-150 were correlated to platelet levels in patients with AF (r = 0.65, p = 0.0087). In conclusion, miR-150 expression levels in platelets of patients with systolic HF with AF are significantly reduced and correlated to the cell-free circulating levels of this miRNA.
Rosetta Genomics, Rehovot, Israel.
Yaron
Y
Goren
Rosetta Genomics, Rehovot, Israel.
Eti
E
Meiri
Rosetta Genomics, Rehovot, Israel.
Christopher
C
Hogan
Rosetta Genomics, Rehovot, Israel.
Heather
H
Mitchell
Rosetta Genomics, Rehovot, Israel.
Danit
D
Lebanony
Heart Failure Center, Department of Cardiovascular Medicine, Lady Davis Carmel Medical Center and Lin Medical Center, Haifa, Israel.
Nabia
N
Salman
Heart Failure Center, Department of Cardiovascular Medicine, Lady Davis Carmel Medical Center and Lin Medical Center, Haifa, Israel.
Jorge E
JE
Schliamser
Heart Failure Center, Department of Cardiovascular Medicine, Lady Davis Carmel Medical Center and Lin Medical Center, Haifa, Israel; Ruth and Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa, Israel. Electronic address: offeram@012.net.il.
Offer
O
Amir
D000368:Aged; D001281:Atrial Fibrillation / Q000097:blood / Q000150:complications / Q000235:genetics*; D001792:Blood Platelets / Q000378:metabolism*; D015716:Electrocardiography, Ambulatory; D005260:Female; D005500:Follow-Up Studies; D005786:Gene Expression Regulation; D054143:Heart Failure, Systolic / Q000097:blood / Q000209:etiology / Q000235:genetics*; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000096:biosynthesis / Q000235:genetics*; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D011379:Prognosis; D012333:RNA, Messenger / Q000235:genetics*
D035683:MicroRNAs; D012333:RNA, Messenger; C533097:MIR150, human